Youssef Garcia-Bengochea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Youssef Garcia-Bengochea has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Angela Li
Division of Cardiology, UCLA Medical Center, Los Angeles, CA 90095, USA
2 shared publications - Avneet Singh
Department of Anesthesia and Intensive Care, Government Medical College and Hospital, Chandigarh, India
1 shared publication - Bani M Azari
Department of Cardiology, North Shore University Hospital, Donald and Barbara Zucker SOM at Hofstra/Northwell, NY, USA
1 shared publication Barry Kaplan
Northwell North Shore University Hospital, Manhasset, NY, USA
1 shared publication- Richard Stechel
Department of Cardiology, North Shore University Hospital, Donald and Barbara Zucker SOM at Hofstra/Northwell, NY, USA
1 shared publication
Latest Publications
- Open Access
- 21 July 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 4 (FI1) , 1-6
Management of COVID-19 myopericarditis with reversal of cardiac dysfunction after blunting of cytokine storm: a case report
Background: Coronavirus disease 2019 (COVID-19) is a syndrome that has been associated with multiple cardiac complications including myopericarditis. The pathophysiology and treatment for myopericarditis in the setting of COVID-19 infection is still under investigation. Case summary: We present a case of a 60-year-old male admitted for dyspnoea due to COVID-19. He developed new ST-segment elevation, elevated cardiac enzymes, severe left ventricular dysfunction, and high inflammatory markers in the setting of haemodynamic and respiratory collapse from the viral illness. He was diagnosed with COVID-19-induced myopericarditis. He showed rapid clinical improvement with a rapid wean off pressure support, resolution of electrocardiogram (ECG) findings, and recovery of left ventricular systolic function following treatment with intravenous immunoglobulin (IVIG) and methylprednisolone. Discussion: COVID-19’s complex and devastating complications continue to create new challenges for clinicians. Cardiac complications, specifically, have been shown to be a signal for worse prognosis in these patients. IVIG and steroids can inhibit the inflammatory cascade and decrease myocardial injury, with implications in treatment of severe myopericarditis.
- 21 July 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 4 (FI1) , 1-6
Open AccessManagement of COVID-19 myopericarditis with reversal of cardiac dysfunction after blunting of cytokine storm: a case report
Background: Coronavirus disease 2019 (COVID-19) is a syndrome that has been associated with multiple cardiac complications including myopericarditis. The pathophysiology and treatment for myopericarditis in the setting of COVID-19 infection is still under investigation. Case summary: We present a case of a 60-year-old male admitted for dyspnoea due to COVID-19. He developed new ST-segment elevation, elevated cardiac enzymes, severe left ventricular dysfunction, and high inflammatory markers in the setting of haemodynamic and respiratory collapse from the viral illness. He was diagnosed with COVID-19-induced myopericarditis. He showed rapid clinical improvement with a rapid wean off pressure support, resolution of electrocardiogram (ECG) findings, and recovery of left ventricular systolic function following treatment with intravenous immunoglobulin (IVIG) and methylprednisolone. Discussion: COVID-19’s complex and devastating complications continue to create new challenges for clinicians. Cardiac complications, specifically, have been shown to be a signal for worse prognosis in these patients. IVIG and steroids can inhibit the inflammatory cascade and decrease myocardial injury, with implications in treatment of severe myopericarditis.